Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
HealthNews
No Result
View All Result
Home Medicine

Higher Antibody Titers Observed With Moderna’s Bivalent Omicron Booster

admin by admin
July 12, 2022
in Medicine


Moderna has announced new clinical data for its bivalent Omicron (BA.1) COVID-19 booster candidate, mRNA-1273.214. The bivalent candidate contains 25mcg of the currently authorized booster (mRNA-1273) and 25mcg of an Omicron subvariant.

Findings showed that 1 month after administration, the 50mcg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against Omicron subvariants BA.4 and BA.5, regardless of prior infection status or age (adults over 18 years old, greater or less than 65 years old), compared with a booster dose of mRNA-1273.

Among individuals without prior infection, significantly higher neutralizing titers against subvariants BA.4 and BA.5 were observed with the bivalent mRNA-1273.214 candidate compared with the currently authorized booster. The geometric mean ratio was 1.69 (95% CI, 1.51-1.90). 


Continue Reading

Findings also showed BA.4/5 neutralizing titers were 775 (95% CI, 719-838) for the bivalent booster candidate and 458 (95% CI, 421-499) for the currently authorized booster at 1 month post vaccination. Compared with prebooster levels, the BA.4 and BA.5 geometric mean fold rise was 6.3-fold (95% CI, 5.7-6.9) for the mRNA-1273.214 group and 3.5-fold (95% CI, 3.2-3.9) for the mRNA-1273 group.

Study results were consistent across subgroups, including participants 65 years of age and older.

“This superior breadth and durability of immune response following a bivalent booster has now been shown in multiple phase 2/3 studies involving thousands of participants,” said Stephane Bancel, Chief Executive Officer of Moderna. “We are working with regulators to advance 2 bivalent vaccine candidates, mRNA-1273.214 and mRNA-1273.222, based on different market preferences for Omicron subvariants, clinical data requirements, and urgency of starting fall booster campaigns for vulnerable populations.”

The Company will also be developing the second bivalent booster candidate, mRNA-1273.222, based on the BA.4/5 strain.

Reference

Moderna’s omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against omicron subvariants BA.4/5 compared to currently authorized booster. News release. Moderna, Inc. Accessed July 11, 2022. https://investors.modernatx.com/news/news-details/2022/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.45-Compared-To-Currently-Authorized-Booster/default.aspx

This article originally appeared on MPR



Source link

Advertisement Banner
Previous Post

Healthy.io receives FDA clearance for smartphone-based home kidney test

Next Post

Sprinkling Salt In Your Meals May Shorten Your Lifespan, Study Finds

Next Post

Sprinkling Salt In Your Meals May Shorten Your Lifespan, Study Finds

Discussion about this post

Recommended

This City Pays $60K Per Tent Supporting Homeless and Crime

3 weeks ago

Alimetry gets FDA clearance for wearable gut disorder test

2 months ago

Don't Miss

Celebrating Health for 25 Years

August 8, 2022

Cherry Tomato Salad | Mark’s Daily Apple

August 8, 2022

Digital gastrointestinal care startup Salvo Health launches with $10.5M

August 8, 2022

Natural Language Processing and Digital Health Transformation, Health News, ET HealthWorld

August 8, 2022

© 2022 Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.